文献速递白血病MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗

髓系白血病干细胞的能量代谢与药物反应

Energy metabolism and drug response in myeloid leukaemic stem cells.
PubMed 文献 · Br J Haematol · 2019-06-24

本文综述髓系恶性肿瘤中白血病干细胞(LSC)的生物学特征,重点讨论能量代谢改变及将其转化为急慢性髓系白血病和骨髓增生异常综合征临床治疗进展的现状。LSC因异质性和与正常造血干细胞表型相似而难以靶向,是目前髓系恶性肿瘤治疗的关键靶点。

要点

  • LSC是髓系恶性肿瘤治疗的关键靶点,但因其异质性和与正常造血干细胞表型相似而难以靶向。
  • 能量代谢改变是LSC生物学的重要方面,正被转化为急慢性髓系白血病和MDS的临床治疗进展。
  • 许多白血病治疗失败的原因在于未能靶向LSC,导致耐药和疾病复发。

核心结论

  • LSC是髓系恶性肿瘤治疗的关键靶点,但因其异质性和与正常造血干细胞表型相似而难以靶向。
  • 能量代谢改变的研究正被转化为急慢性髓系白血病和骨髓增生异常综合征的临床治疗进展。

研究设计与样本

  • 综述,聚焦髓系恶性肿瘤中LSC生物学及能量代谢改变向临床转化的现状。

主要发现

  • 许多髓系恶性肿瘤患者对治疗耐药并最终死于疾病。
  • 越来越多证据提示许多白血病治疗不足源于未能靶向LSC。
  • LSC因群体内异质性和与正常造血干细胞表型相似而成为最难靶向的群体。

临床怎么用

  • LSC是目前髓系恶性肿瘤治疗中最关键的靶点。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite significant advances in the treatment of myeloid malignancies, many patients become resistant to therapy and ultimately succumb to their disease. Accumulating evidence over the past several years has suggested that the inadequacy of many leukaemia therapies results from their failure to target the leukaemic stem cell (LSC). For this reason, the LSC population currently represents the most critical target in the treatment of myeloid malignancies. However, while LSCs are ideal targets in the treatment of these diseases, they are also the most difficult population to target. This is due to both their heterogeneity within the LSC population, and also their phenotypic similarities with normal haematopoietic stem cells. This review will highlight the current landscape surrounding LSC biology in myeloid malignancies, with a focus on altered energy metabolism, and how that knowledge is being translated into clinical advances for the treatment of chronic and acute myeloid leukaemia and myelodysplastic syndromes.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Bencomo-Alvarez AE, Rubio AJ, Gonzalez MA, et al. Energy metabolism and drug response in myeloid leukaemic stem cells. Br J Haematol. 2019. PMID: 31236939. doi:10.1111/bjh.16074

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。